Latest moves, page 2
- RSKD Up 22.3% New
Riskified jumps 22% as revenue growth nearly doubles to 41%
Riskified rose about 22% after Q3 revenue grew 41%, led by new merchants in digital finance, and it raised its 2026 forecast for the third time.
- LEGN Down 16% New
Legend Biotech falls 16% as it tempers expectations for Carvykti sales
Legend Biotech's finance chief said analysts' Carvykti sales forecasts for the fourth quarter and 2027 sit at the high end of its own scenarios, citing slower US uptake.
-
Nvidia without Jensen Huang: his grip, the missing heir and history
Huang led Nvidia from 1993 until his resignation, announced Nov 12, 2026; its CFO is interim CEO. What founder hand-overs from Jobs to Bezos show, and what they can't.
-
Rocket Lab Q3 2026: backlog up 52% to $3.6 billion as Neutron slips into 2027
Rocket Lab's sales beat its own range and backlog jumped 52%, but Neutron's first launch, which management ties to stand-alone adjusted profit, moved into 2027.
-
Hims & Hers Q3 2026: sales up 49%, but margins slide, subscribers dip and profit outlook cut
Hims & Hers grew sales 49% on weight loss and Eucalyptus, but gross margin fell to 57%, subscribers dipped from Q2 and it cut its 2026 profit outlook.
- APPS Down 35.8% New
Digital Turbine falls 36% as margins shrink despite a revenue beat
Digital Turbine beat revenue estimates and raised its sales forecast, but its adjusted gross margin fell to 43%, its profit forecast stayed put and it revised past costs.
- SECZ Up 22.4% New
Securitize jumps 22% as it agrees to buy River One and plans a $50M buyback
Securitize rose about 22% after Q3 results, a deal to buy lending platform River One on undisclosed terms, and a $50M buyback against about $299M of cash.
- FRVO Up 26.1% New
Fervo jumps 26% as it pushes spending later and its next plant syncs
Fervo closed up 26% after cutting its second-half spending plan by $150M, which it says is timing, not savings, and reporting progress at its Utah plant.
- ARWR Down 15.3% New
Arrowhead falls 15% the day its closest rival halves a sales forecast
Arrowhead fell 15% the day Ionis halved its forecast for a competing drug; no source established why, and Arrowhead's headline trial results were already public.
-
TG Therapeutics Q3 2026: Briumvi target raised again, but sales growth slows to 2% from Q2
TG Therapeutics raised its 2026 Briumvi target for the third time, to $915–920 million, but US sales rose only 2% from Q2 and the rest of the raise rests on Q4.
- IBRX Down 17.7% New
ImmunityBio falls 18% as Anktiva sales slip, overshadowing a trial win
ImmunityBio's Anktiva sales fell from Q2 and total revenue missed estimates by about $10 million, overshadowing a bladder-cancer trial win the same morning.
-
Did money leave US stocks for gold? What the flows show
Gold's value rose about as much as US stocks' in 2025, yet foreigners bought a record $742 billion of US stocks. The dollar's retreat is in official Treasury holdings.
-
Unity Software triples since its AI-scare low as Vector ads beat forecasts
Unity's shares have tripled since February, mostly winning back an AI-driven slump, as its Vector ad engine kept beating forecasts; they are up 17% this year.
-
Caterpillar gives back its AI rally, down 48% since June
Caterpillar has lost almost half its value since its June record despite a record backlog. Data-center power stocks fell too; about 13 points go beyond their average.
-
The $6 billion test: what crypto is for, and where it could go from here
A record theft at Binance shows how far crypto has moved from its origins. What it's used for, by the numbers, who regulates it, and four paths from here.
- KRMN Up 42.1% New
Karman jumps 42% after record backlog and a two-day post-election slide
Karman's Q3 revenue rose 66% and backlog hit a record $1.7 billion, but its forecast rose about 3% and its Lockheed deal was already public. Peers rose far less.
-
Coinbase: our view and what our model says about 2030
Our analysis of Coinbase after Q3: crypto trading, USDC income, prediction markets, stock pay and what 50,000 simulations say about end-2030 value.
- IRTC Down 30.7% New
iRhythm falls 31% as FDA filing slips and its raise leans on an acquisition
iRhythm raised its 2026 revenue outlook only because of an acquisition, delayed its Zio MCT filing to 2027 and said its Zio AT patch stopped growing.
- FLY Up 36.8% UPDATED NOV 10New
Firefly jumps about 37% on a $1.3B engine deal with AST SpaceMobile
Firefly closed up about 37% on a $1.3B-plus AST SpaceMobile deal. About $400M is cash for the license, paid against milestones; most revenue starts in 2027, Firefly says.
-
Immunocore Q3 2026: sales dip after Q2 stocking; key melanoma trial data slips to Q2 2027
Immunocore's Kimmtrak sales fell 12% from Q2 to $102.2 million after a stocking boost, and it now expects its key melanoma trial data in Q2 2027.